405 related articles for article (PubMed ID: 30719168)
1. Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer.
Chen S; Zhang N; Shao J; Wang T; Wang X
J Cancer; 2019; 10(3):697-707. PubMed ID: 30719168
[No Abstract] [Full Text] [Related]
2. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.
Chen YP; Zhang Y; Lv JW; Li YQ; Wang YQ; He QM; Yang XJ; Sun Y; Mao YP; Yun JP; Liu N; Ma J
Theranostics; 2017; 7(14):3585-3594. PubMed ID: 28912897
[TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration.
Ock CY; Keam B; Kim S; Lee JS; Kim M; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS
Clin Cancer Res; 2016 May; 22(9):2261-70. PubMed ID: 26819449
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type.
Koh J; Nam SK; Roh H; Kim J; Lee BC; Kim JW; Ahn SH; Park DJ; Kim HH; Park KU; Chung JH; Kim WH; Lee HS
Genes Chromosomes Cancer; 2019 Jan; 58(1):12-22. PubMed ID: 30239046
[TBL] [Abstract][Full Text] [Related]
5. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
6. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
Noh BJ; Kwak JY; Eom DW
BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
[TBL] [Abstract][Full Text] [Related]
7. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
8. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
9. TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
Jin K; Xu J; Su X; Xu Z; Li B; Liu G; Liu H; Wang Y; Zhu Y; Xu L; Zhang W; Liu Z; Wang Z; Chang Y; Xu J
J Pathol; 2024 Jun; 263(2):139-149. PubMed ID: 38380548
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of immune classification in a multicentre cohort of patients with small intestinal adenocarcinoma.
Noh BJ; Hong SM; Jun SY; Eom DW
Pathology; 2020 Feb; 52(2):228-235. PubMed ID: 31685233
[TBL] [Abstract][Full Text] [Related]
11. Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression.
Lin Z; Gu J; Cui X; Huang L; Li S; Feng J; Liu B; Zhou Y
J Cancer; 2019; 10(1):211-222. PubMed ID: 30662542
[No Abstract] [Full Text] [Related]
12. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.
Jing W; Wang G; Cui Z; Xiong G; Jiang X; Li Y; Li W; Han B; Chen S; Shi B
Cancer Res; 2022 Jan; 82(1):114-129. PubMed ID: 34753771
[TBL] [Abstract][Full Text] [Related]
13. Correlation Between Dual-Time-Point FDG PET and Tumor Microenvironment Immune Types in Non-Small Cell Lung Cancer.
Zhou J; Zou S; Cheng S; Kuang D; Li D; Chen L; Liu C; Yan J; Zhu X
Front Oncol; 2021; 11():559623. PubMed ID: 33816219
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes.
Noh BJ; Kim JH; Eom DW
Ann Clin Lab Sci; 2018 Nov; 48(6):695-706. PubMed ID: 30610038
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
16. Estrogen Receptor Downregulates Expression of PD-1/PD-L1 and Infiltration of CD8
Shuai C; Yang X; Pan H; Han W
Front Oncol; 2020; 10():582863. PubMed ID: 33102239
[No Abstract] [Full Text] [Related]
17. Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes.
Liao H; Chen W; Dai Y; Richardson JJ; Guo J; Yuan K; Zeng Y; Xie K
Front Oncol; 2019; 9():883. PubMed ID: 31572677
[TBL] [Abstract][Full Text] [Related]
18. Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8
Zhu Y; Wang XY; Zhang Y; Xu D; Dong J; Zhang Z; Yi CH; Jia HL; Yang X
Cancer Manag Res; 2018; 10():4113-4123. PubMed ID: 30323667
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
20. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
